Title:
COMPOSITION FOR PREVENTING OR TREATING METABOLIC LIVER DISEASE
Document Type and Number:
WIPO Patent Application WO/2021/020841
Kind Code:
A1
Abstract:
The present invention relates to a pharmaceutical composition for preventing or treating non-alcoholic fatty liver disease, comprising ulixertinib. The composition of the present invention, which comprises ulixertinib, reduces steatosis, inflammation, and ballooning in liver tissue where non-alcoholic fatty liver has been induced; reduces the level of fibrosis of inflammation induced by non-alcoholic fatty liver; and reduces the weight of a liver that has increased due to non-alcoholic fatty liver disease. Accordingly, the composition of the present invention can be provided for use in preventing or treating metabolic liver disease, including non-alcoholic fatty liver disease.
Inventors:
HAN DAEHEE (KR)
KOO HEE JUNG (KR)
KIM JINHAN (KR)
SONG SANG OK (KR)
YUN SO JEONG (KR)
KOO HEE JUNG (KR)
KIM JINHAN (KR)
SONG SANG OK (KR)
YUN SO JEONG (KR)
Application Number:
PCT/KR2020/009862
Publication Date:
February 04, 2021
Filing Date:
July 27, 2020
Export Citation:
Assignee:
STANDIGM INC (KR)
International Classes:
A61K31/4439; A61K45/06; A61P1/16
Domestic Patent References:
| WO2017017677A1 | 2017-02-02 | |||
| WO2003091246A1 | 2003-11-06 | |||
| WO2016123574A1 | 2016-08-04 |
Foreign References:
| US20060106069A1 | 2006-05-18 |
Other References:
CHOI EUNO, KIM WON, JOO SAE KYUNG, PARK SUNYOUNG, PARK JEONG HWAN, KANG YUN KYUNG, JIN SO-YOUNG, CHANG MEE SOO: "Expression patterns of STAT3, ERK and estrogen-receptor α are associated with development and histologic severity of hepatic steatosis: a retrospective study", DIAGNOSTIC PATHOLOGY, vol. 13, no. 1, 23, 3 April 2018 (2018-04-03), pages 1 - 9, XP055776864, DOI: 10.1186/s13000-018-0698-8
Attorney, Agent or Firm:
HANOL INTELLECTUAL PROPERTY AND LAW (KR)
Download PDF: